TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

About this update from Tg Therapeutics, Inc.

[{"type":"image","alt":"TG Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TG Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SDBygDD99LtQB0oJDC8xZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1","width":300,"height":79}},"lazy":false},{"type":"text","content":"First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million","length":135,"tagName":"p"},{"type":"text","content":"Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S. net product revenue target to $885-900 million","length":165,"tagName":"p"},{"type":"text","content":"Conference call to be held today, Wednesday, May 6, 2026, at 8:30 AM ET ","length":76,"tagName":"p"},{"type":"text","content":"NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance.","length":271,"tagName":"p"},{"type":"text","content":"Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “We are off to a strong start in 2026, with BRIUMVI performance exceeding expectations and momentum continuing to build. Growth is being driven by strong underlying demand, record new patient starts, and consistent commercial execution— reinforcing our belief that we remain early in the adoption curve for BRIUMVI. Based on this performance, we are significantly increasing our full-year U.S. BRIUMVI revenue guidance to $885-900 million and continue to see the brand as having a multi-billion-dollar potential before considering the impact of a subcutaneous BRIUMVI currently under development. With multiple near-term clinical catalysts and ongoing efforts to expand the franchise, we believe BRIUMVI is well-positioned to become a leading therapy in MS and a durable, long-term growth driver for TG.”Recent Highlights & Developments","length":920,"tagName":"p"},{"type":"text","content":"B...

More updates from Tg Therapeutics, Inc.